Joan E Humphreys - JoVE Visualize

Showing results (1-10 of 15) with videos related to

Pageof 2

Sort By:

Journal of Pharmaceutical Sciences|March 5, 2004

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship modelVijay K Gombar, Joseph W Polli, Joan E Humphreys, et al.

Journal of Pharmaceutical Sciences|September 7, 2004

In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidatesVictoria E Thiel-Demby, Timothy K Tippin, Joan E Humphreys, et al.

The Journal of Pharmacology and Experimental Therapeutics|July 22, 2006

Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the ratMaciej J Zamek-Gliszczynski, Keith A Hoffmaster, Joan E Humphreys, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2015

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolamMelinda J Reese, Gary D Bowers, Joan E Humphreys, et al.

Molecular Pharmaceutics|February 28, 2009

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assayVictoria E Thiel-Demby, Joan E Humphreys, Lisa A St John Williams, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2006

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substratesJarkko Rautio, Joan E Humphreys, Lindsey O Webster, et al.

Journal of Pharmaceutical Sciences|September 23, 2003

P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamineJoseph W Polli, Todd M Baughman, Joan E Humphreys, et al.

The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugsKelly M Mahar Doan, Joan E Humphreys, Lindsey O Webster, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2008

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsJoseph W Polli, Joan E Humphreys, Kelly A Harmon, et al.

Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:

Pageof 2

Journal of Pharmaceutical Sciences|March 5, 2004

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship modelVijay K Gombar, Joseph W Polli, Joan E Humphreys, et al.

Journal of Pharmaceutical Sciences|September 7, 2004

In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidatesVictoria E Thiel-Demby, Timothy K Tippin, Joan E Humphreys, et al.

The Journal of Pharmacology and Experimental Therapeutics|July 22, 2006

Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the ratMaciej J Zamek-Gliszczynski, Keith A Hoffmaster, Joan E Humphreys, et al.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 5, 2015

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolamMelinda J Reese, Gary D Bowers, Joan E Humphreys, et al.

Molecular Pharmaceutics|February 28, 2009

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assayVictoria E Thiel-Demby, Joan E Humphreys, Lisa A St John Williams, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2016

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy SubjectsIvy H Song, Jian Zong, Julie Borland, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2006

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substratesJarkko Rautio, Joan E Humphreys, Lindsey O Webster, et al.

Journal of Pharmaceutical Sciences|September 23, 2003

P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamineJoseph W Polli, Todd M Baughman, Joan E Humphreys, et al.

The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugsKelly M Mahar Doan, Joan E Humphreys, Lindsey O Webster, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2008

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsJoseph W Polli, Joan E Humphreys, Kelly A Harmon, et al.

Pageof 2